We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-8.37%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.28B
AUM Growth
-$1.41B
Cap. Flow
-$1.19B
Cap. Flow %
-22.61%
Top 10 Hldgs %
53.54%
Holding
466
New
23
Increased
24
Reduced
24
Closed
360

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$72.5M
2
LEGN icon
Legend Biotech
LEGN
+$64.3M
3
OSCR icon
Oscar Health
OSCR
+$64.1M
4
DVAX
Dynavax Technologies
DVAX
+$62.6M
5
INDV icon
Indivior Pharmaceuticals
INDV
+$39M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$187M
2
KURA icon
Kura Oncology
KURA
+$106M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$66.5M
4
SGRY icon
Surgery Partners
SGRY
+$57.4M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$56.2M

Sector Composition

Rank Sector Weight
1 Healthcare 87.97%
2 Industrials 0.23%
3 Consumer Staples 0.01%
4 Energy 0%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
1
DELISTED
Nuvalent
NUVL
$1.41B 26.67%
17,991,024
-2,000,000
-10% -$187M
VTRS icon
2
Viatris
VTRS
$20.1B
$299M 5.66%
23,996,036
+3,013
+0% +$37K
CNC icon
3
Centene
CNC
$32.8B
$162M 3.07%
2,671,921
+19,732
+0.7% +$1.23M
OSCR icon
4
Oscar Health
OSCR
$8.77B
$159M 3.01%
11,835,000
+3,983,325
+51% +$64.1M
RVMD icon
5
Revolution Medicines
RVMD
$39.6B
$143M 2.7%
3,258,332
+345,640
+12% +$17.4M
MRUS
6
DELISTED
Merus
MRUS
$125M 2.37%
2,972,787
-435,752
-13% -$20.9M
WAY
7
Waystar Holding Corp
WAY
$4.27B
$121M 2.29%
3,295,260
-1,656,744
-33% -$50.9M
NBIX icon
8
Neurocrine Biosciences
NBIX
$17.2B
$118M 2.23%
862,000
-454,590
-35% -$56.2M
SPRY icon
9
ARS Pharmaceuticals
SPRY
$695M
$111M 2.1%
10,514,657
-563,270
-5% -$7.89M
NAMS icon
10
NewAmsterdam Pharma
NAMS
$3.7B
$111M 2.1%
4,314,340
+3,412,590
+378% +$72.5M
INDV icon
11
Indivior Pharmaceuticals
INDV
$4.79B
$110M 2.09%
8,883,160
+3,790,518
+74% +$39M
AHCO icon
12
AdaptHealth
AHCO
$1.49B
$92.5M 1.75%
9,711,410
– –
ALHC icon
13
Alignment Healthcare
ALHC
$4.26B
$82.2M 1.56%
7,304,302
-3,550,683
-33% -$41.5M
LRMR icon
14
Larimar Therapeutics
LRMR
$384M
$82.2M 1.56%
21,231,974
– –
BKD icon
15
Brookdale Senior Living
BKD
$3.58B
$78.5M 1.49%
15,612,264
– –
IDYA icon
16
IDEAYA Biosciences
IDYA
$3.47B
$70.3M 1.33%
2,736,000
+142,000
+5% +$4.02M
EMBC icon
17
Embecta
EMBC
$193M
$67.5M 1.28%
3,270,535
+540,192
+20% +$8.85M
DVAX
18
DELISTED
Dynavax Technologies
DVAX
$66.3M 1.26%
5,193,823
+5,172,263
+23,990% +$62.6M
CPRX
19
DELISTED
Catalyst Pharmaceutical
CPRX
$65.4M 1.24%
3,133,011
-3,096,623
-50% -$66.5M
ACH
20
Accendra Health
ACH
$266M
$64.2M 1.22%
4,911,979
– –
BCRX icon
21
BioCryst Pharmaceuticals
BCRX
$2.36B
$61.2M 1.16%
8,144,442
+8,638
+0.1% +$65.6K
BAX icon
22
Baxter International
BAX
$11.7B
$56.1M 1.06%
1,923,100
– –
EWTX icon
23
Edgewise Therapeutics
EWTX
$4.28B
$55.5M 1.05%
2,078,509
+297,503
+17% +$9.47M
LEGN icon
24
Legend Biotech
LEGN
$4.31B
$50.5M 0.96%
+1,551,718
New +$64.3M
BIO icon
25
Bio-Rad Laboratories Class A
BIO
$8.15B
$49.8M 0.94%
151,644
+69
+0% +$23.4K
1
2 3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2024 Portfolio in Review

As of Q4 2024, Deerfield Management held 466 positions worth $5.28B, down 21% from $6.69B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $1.19B in Q4 2024, closing 360 positions and reducing 24 holdings. Its most notable exit was Kura Oncology, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 87% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Deerfield Management opened a new position in Legend Biotech worth $50.5M.

  • Deerfield Management's largest Q4 2024 buy was Legend Biotech: 1,551,718 shares worth $50.5M.
  • Deerfield Management added most to NewAmsterdam Pharma in Q4 2024, an estimated $72.5M increase.
  • Deerfield Management's biggest Q4 2024 reduction was Nuvalent, cutting an estimated $187M.
  • Deerfield Management fully exited Kura Oncology in Q4 2024, selling an estimated $106M.
  • Deerfield Management's ten largest holdings make up 54% of its $5.28B portfolio in Q4 2024.
  • Deerfield Management opened 23 new positions and closed 360 in Q4 2024.
  • Deerfield Management's portfolio value fell 21% quarter-over-quarter to $5.28B.

Based on Deerfield Management's 13F filing for Q4 2024, filed 14 Feb 2025.